2-Bromo-5-methylbenzoic acid

In reported synthetic methodology, 2‑bromo‑5‑methylbenzoic acid is coupled with a pyrimidine derivative (such as 2‑chloropyrimidine) using palladium‑catalyzed cross‑coupling (e.g., Negishi coupling) to form 5‑methyl‑2‑(pyrimidin‑2‑yl)benzoic acid, which is an important molecular fragment incorporated into the Filorexant API’s structure. 2‑Bromo‑5‑methylbenzoic acid is employed to synthesize Filorexant (MK‑6096), a dual orexin receptor antagonist that was developed for the treatment of insomnia.